HHLR ADVISORS, LTD. Q3 2023 significant ownership

Add to watchlist

HHLR ADVISORS, LTD. is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

HHLR ADVISORS, LTD. Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
I-MabJune 30, 202315,891,2118.3%
BeiGene, Ltd.February 14, 2023147,043,05810.9%
Gossamer Bio, Inc.February 14, 20234,974,0415.3%
On Holding AGFebruary 14, 20235,468,5041.9%
Root, Inc.February 14, 2023138,9771.5%
Yatsen Holding LtdFebruary 14, 2023300,560,60219.1%
iQIYI, Inc.July 11, 2022149,075,9125.0%
Apellis Pharmaceuticals, Inc.February 14, 2022? ?
Beam Therapeutics Inc.February 14, 2022? ?
Futu Holdings LtdFebruary 14, 20222-
KE Holdings Inc.February 14, 202289,085,1953.3%
LEAP THERAPEUTICS, INC.February 14, 2022? ?
MINISO Group Holding LtdFebruary 14, 20221,009,2900.1%
TAL Education GroupFebruary 14, 2022? ?
Enstar Group LTDJuly 19, 2021? ?
China Biologic Products Holdings, Inc.Sold outApril 22, 202100.0%
Bilibili Inc.February 16, 20215,067,0272.1%
Futu Holdings LtdFebruary 16, 20211,200,0000.2%
Viela Bio, Inc.February 16, 20212,382,4144.3%
Cellular Biomedicine Group, Inc.June 24, 2020235,2141.2%

Compare quarters

Export HHLR ADVISORS, LTD.'s holdings

CSVXLS